Earnings per share for the last twelve months: Ikena Oncology Inc. (IKNA)

Ikena Oncology, Inc. (IKNA) focuses on the metabolic treatment of tumors, protecting future sales with patents. The environmental footprint is minimized through digital document management and laboratory safety. The annual net income per share trend visualizes the results of this development, where the value of -7.61 reflects this status. Efficiency is maintained by outsourcing drug synthesis to third-party CMOs, which eliminates infrastructure risks.
Summary analytical data breakdowns for Ikena (IKNA)

Ikena Oncology, Inc. (IKNA) operates in the high-risk biopharmaceutical sector. This indicator reflects the final financial result allocated per common share on a rolling year basis. By analyzing the annual net income per share trend, an investor can observe the actual capitalization efficiency and the real cash burn. The negative trend here confirms the costs of clinical trials and the strategic pivot. In the long term, this metric will serve as a marker in the event of a company liquidation or merger.